Transaortic transcatheter aortic valve replacement with the Sapien™ valve and the first generations of Ascendra™ by Ferrari, Enrico et al.
Transaortic transcatheter aortic valve replacement with the
Sapien™ valve and the ﬁrst generations of Ascendra™
Enrico Ferrari*, Denis Berdajs, Piergiorgio Tozzi and René Prêtre
Cardiac surgery unit, University Hospital of Lausanne, Lausanne, Switzerland
* Corresponding author. Cardiac surgery unit, University Hospital of Lausanne (CHUV), 46 Rue du Bugnon, CH-1011 Lausanne, Switzerland. Tel: +41-793101386;
fax: +41-213142278; e-mail: enricoferrari@bluewin.ch (E. Ferrari).
Received 2 April 2013; received in revised form 26 April 2013; accepted 1 May 2013
Abstract
Traditionally, the transcatheter aortic valve replacement is performed through a transapical, a transfemoral or a trans-subclavian approach.
Recently, the transaortic approach for transcatheter aortic valve replacement through the distal part of the ascending aorta was successfully
implemented in order to avoid peripheral vascular access-related complications and apical life-threatening haemorrhage. The Sapien™
stent valve has great transaortic potential because it can be loaded ‘upside down’ in different generations of delivery systems. However,
because of their health regulatory systems and despite the launch, in 2012, of the latest generation of the Ascendra™ delivery system, the
Ascendra+™, speciﬁcally designed for transapical and transaortic valve placements, several countries are still using the ﬁrst generations of
Ascendra™ (Ascendra™ 1 and 2). This device was speciﬁcally designed for transapical procedures, and retrograde stent-valve positioning
through the stenotic aortic valve may be very challenging and risk the integrity of the aorta. We describe the manoeuvre required in order
to pass the stenotic aortic valve safely in a retrograde direction using the Sapien™ stent valve and the ﬁrst generations of Ascendra™.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is a successful
procedure for inoperable patients and patients at high risk
for surgery [1, 2]. Three access sites have been successfully
employed for this procedure, namely the transapical (TA), the
transfemoral (TF) and the trans-subclavian access. Nevertheless,
some concerns have risen about the risk of life-threatening
apical bleeding or apical dysfunction/scar/pseudo-aneurysm
after TA-TAVR, and the risk of severe access-related vascular
complications after TF-TAVR and trans-subclavian procedures
[3, 4]. Recently, a technique combining the advantages of all
transcatheter procedures without carrying their disadvantages
was implemented in experienced centres; this technique is
the transaortic approach (TAO-TAVR) through an upper
mini-sternotomy or a right mini-thoracotomy at the second
intercostal space [5, 6]. Both self-expandable (Corevalve;
Medtronic, Minneapolis, MN, USA) and balloon-expandable
valves (Sapien™ THV; Edwards Lifesciences, Irvine, CA, USA)
were tested with good results [5–8]. In particular, the new
Ascedra+™ delivery system for Sapien™ was speciﬁcally designed
for this purpose. However, in several countries (in particular in
the USA) the Sapien™ is still implanted using the Ascendra™ ﬁrst
generations only (Ascendra™ 1 and, later, the Ascendra™ 2), a
tool designed to cross the valve in an antegrade direction. We
describe the manoeuvre that represents a ‘key point’ allowing
TAVR teams to cross the valve in a retrograde direction with the
old system during TAO-TAVR.
TECHNIQUE
The ﬁrst generations of Ascendra™ (Edwards Lifesciences), the
Ascendra™ 1 and 2, have structural differences compared with the
new Ascendra+™. In particular, they were not designed to enter
vessels, and the distal part of the balloon catheter did not incorp-
orate a nose-cone to facilitate retrograde valve crossing (Fig. 1A).
Thus, in order to perform TAO-TAVR procedures, some centres
used the Retroﬂex™ (Edwards Lifesciences), a delivery system
designed to perform TF-TAVR. However, the Retroﬂex™ requires
challenging manipulations when placed behind the patient’s right
shoulder due to its extensive length, and the procedure becomes
more complex, with less stability, less precision and the risk of loss
of sterility. As a consequence, the ﬁrst generations of Ascendra™
were employed, and the following manoeuvre was developed in
order to cross the valve in a retrograde direction.
(i) After placing the super-stiff guidewire through the valve, the
6 French sheet is replaced by the Ascendra™.
(ii) In order to avoid damage to the ascending aorta, vascular
dilators are used to enlarge the hole (the set suggested for
TF-TAVR or sets for percutaneous arterial cannulation). In
this phase, bleeding is controlled by manipulating the aorta
or by tying purse-string sutures, with concomitant blood
pressure control.
(iii) The Ascendra™ is gently inserted into the ascending aorta,
with rotational manipulations to cross the wall thickness.
Care is required to avoid aortic dissection.
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(iv) Once the Ascendra™ has been inserted (1–2 cm) and the
white dilator removed, the sheet is attached to the purse-
string sutures as in standard aortic cannulation. This will
prevent involuntary displacement of the delivery system.
(v) Through the Ascendra™, the balloon is inserted, and the
aortic valvuloplasty is performed following standard guide-
lines.
(vi) After the balloon is removed, the stitch ﬁxing the Ascendra™
to the purse-string sutures is removed and the white dilator
is repositioned inside the sheet.
(vii) Under ﬂuoroscopic control, the sheet and the dilator are
placed, over the wire, deep into the ascending aorta,
through the diseased aortic valve (Fig. 1B). The radiopaque
tip markers have to lie in the left ventricular outﬂow tract.
(viii) The dilator is removed and the sheet left in place across
the valve. Usually, this manoeuvre does not interfere with
haemodynamics.
Figure 1: (A) The tip of the old generation Ascendra™ 1 (left) compared with
the nose-cone of the new Ascendra+™ (right). (B) Over the wire, the ﬁrst gener-
ation of Ascendra™ is placed through the stenotic aortic valve using the white
dilator to cross the valve easily in a retrograde direction. The tip markers of the
Ascendra™ should lie in the left ventricular outﬂow tract. (C) The white dilator is
retrieved, and the loader carrying the crimped valve is connected to the
Ascendra™. Then, the Sapien™ valve is placed across the diseased aortic valve
under ﬂuoroscopic control.
Figure 2: (A) The Ascendra™ is retrieved and parked in the distal ascending
aorta while the crimped stent valve is left in place across the diseased aortic
valve. (B) The Sapien™ is placed following standard guidelines.
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(ix) The valve loader is connected, and the crimped valve is
inserted and placed across the aortic valve under ﬂuoro-
scopic control, still covered by the sheet (Fig. 1C).
(x) The balloon catheter with the valve is left in place while the
Ascendra™ is retrieved into the ascending aorta. In this
phase, extreme care is required not to displace the stent
valve and not to extract the Ascendra™ completely (Fig. 2A).
Then, the sheet is reﬁxed to the purse-string sutures.
(xi) The pusher is retrieved without displacing the Sapien™.
Then, the valve is positioned and delivered following stand-
ard guidelines (Fig. 2B).
To date, several TAO-TAVR cases have been successfully per-
formed in Europe using the ﬁrst generations of Ascendra™
(Ascendra™ 1 and 2) and the above-described manoeuvre.
CONCLUSION
Transaortic TAVR is a promising approach for transcatheter valve
replacement because the risk of peripheral vascular damage and
apical bleeding is dramatically reduced. Moreover, compared
with TF-TAVR or TA-TAVR, the aortic arch is much less stressed by
guidewires, catheters and delivery systems, and this potentially
reduces the risks of neurological complications. Reported aortic
dissections can be attributed to an earlier phase (without the use
of this manoeuvre and before the launch of the new Ascendra+™)
or to the introduction of the sheet into the aorta (dilators can
help). The Sapien™ stent valve has great potential in TAO-TAVR,
and several implants have already been performed worldwide [5–
8]. However, the new Ascendra+™ is engineered for this approach,
whereas the ﬁrst generations were not; thus, in order to cross the
valve safely in a retrograde direction the manoeuvre described
represents a ‘key factor’ for all Ascendra™ 1 and 2 users [owing to
different health regulatory systems, these ﬁrst generations of
Ascendra™ are the only ones available in several countries (e.g.
USA), and they can still be employed safely in TAO-TAVR].
In conclusion, the technique described is safe, reproducible and
easy and it allows TAVR teams using the Sapien™ platform to treat
patients with a tailored approach, regardless of the generation of
the medical device employed.
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